A
3.47
0.00 (0.00%)
Previous Close | 3.47 |
Open | 3.45 |
Volume | 133,080 |
Avg. Volume (3M) | 864,811 |
Market Cap | 696,064,704 |
Price / Earnings (TTM) | 28.92 |
Price / Earnings (Forward) | 18.05 |
Price / Sales | 0.990 |
Price / Book | 3.86 |
52 Weeks Range | |
Earnings Date | 26 Feb 2025 - 5 Mar 2025 |
TTM Dividend Yield | 3.49% |
Profit Margin | 3.44% |
Operating Margin (TTM) | 10.90% |
Diluted EPS (TTM) | 0.120 |
Quarterly Revenue Growth (YOY) | 6.60% |
Quarterly Earnings Growth (YOY) | 81.10% |
Total Debt/Equity (MRQ) | 173.77% |
Current Ratio (MRQ) | 0.640 |
Operating Cash Flow (TTM) | 159.59 M |
Levered Free Cash Flow (TTM) | 158.20 M |
Return on Assets (TTM) | 6.67% |
Return on Equity (TTM) | 13.84% |
Market Trend
Short Term | Medium Term | ||
Industry | Diagnostics & Research (AU) | Mixed | Mixed |
Diagnostics & Research (Global) | Mixed | Mixed | |
Stock | AUCLINICAL FPO [ACL] | - | - |
AIStockmoo Score
-1.1
Analyst Consensus | 0.0 |
Insider Activity | NA |
Price Volatility | -1.5 |
Technical Moving Averages | -2.5 |
Technical Oscillators | -0.5 |
Average | -1.13 |
Australian Clinical Labs, or ACL, is Australia’s third-largest private pathology provider. ACL earns almost its entire group revenue from pathology services in Australia, which are mostly earned via the publicly funded health Medicare system. ACL is well-established in the states of Western Australia, South Australia, Victoria and the Northern Territory. |
|
Sector | Healthcare |
Industry | Diagnostics & Research |
Investment Style | Small Core |
% Held by Insiders | 4.84% |
% Held by Institutions | 51.39% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2025 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |